Traws Pharma, Inc. (TRAW) Income Statement
TRAW 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTRAW revenue and net income
Where TRAW's revenue goes
2025Each bar shows an amount and its share of revenue. TRAW kept 328.7% of revenue as net income.
TRAW profit margins
TRAW growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +1,134.5% | +131.1% | +64.6% | −13.2% |
| Gross profit | +1,203.7% | +131.1% | +64.6% | −13.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TRAW quarterly EPS vs estimates
Traws Pharma beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.21).
TRAW income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 | $231,000 | $2.2M | $1.2M | $787,000 | $5.5M |
| Cost of revenue | $61,000 | $12,000 | $16,000 | $14,000 | $14,000 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $2.8M | $214,000 | $226,000 | $226,000 | $226,000 | $231,000 | $2.2M | $1.2M | $787,000 | $5.5M |
| Research & development | $12.1M | $130.3M | $11.4M | $11.4M | $7.3M | $16.9M | $15.5M | $16.9M | $19.0M | $20.1M |
| Sales, general & admin | $8.5M | $12.3M | $9.1M | $8.4M | $9.4M | $8.3M | $8.3M | — | — | — |
| Total operating expenses | $20.7M | $49.6M | $20.5M | $19.9M | $16.7M | $25.2M | $23.9M | $24.5M | $26.4M | $29.2M |
| Operating income | −$17.9M | −$49.3M | −$20.3M | −$19.6M | −$16.5M | −$25.0M | −$21.7M | −$23.3M | −$25.7M | −$23.7M |
| Income before taxes | $9.2M | −$166.5M | −$18.9M | −$19.0M | −$16.2M | −$25.2M | −$21.5M | −$20.5M | −$24.1M | −$19.7M |
| Income taxes | — | — | −$151,895 | −$214,485 | −$321,000 | $4,000 | $10,000 | −$124,000 | $13,000 | $14,000 |
| Net income | $9.2M | −$54.7M | −$18.9M | −$19.0M | −$16.2M | −$25.2M | −$21.5M | −$20.6M | −$24.1M | −$19.7M |
| EBITDA | −$17.8M | −$166.5M | −$20.3M | −$19.6M | −$16.5M | −$25.0M | −$21.7M | −$20.5M | −$24.0M | −$19.6M |
| EPS (diluted) | $1.04 | −$108.96 | −$17.94 | −$16.51 | −$12.72 | −$48.75 | −$988.85 | −$752.33 | −$15862.50 | −$30975.74 |
| Gross margin | 100.0% | 94.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −640.7% | −21,835.4% | −8,981.4% | −8,684.5% | −7,299.1% | −10,819.5% | −994.0% | −1,895.9% | −3,270.3% | −427.4% |
| Net margin | 328.7% | −24,192.0% | −8,384.1% | −8,391.2% | −7,151.8% | −10,890.5% | −985.0% | −1,675.3% | −3,061.2% | −354.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $57,000 | $0 | $0 | $2.7M | $57,000 | $57,000 | $57,000 | $56,000 | $56,000 | $113,000 | $57,000 |
| Cost of revenue | — | $0 | — | — | $1,000 | $1,000 | $2,000 | $2,000 | $4,000 | $4,000 | $4,000 | $5,000 |
| Gross profit | — | $57,000 | — | — | $2.7M | $56,000 | $55,000 | $55,000 | $56,000 | $56,000 | $109,000 | $57,000 |
| Research & development | $1.1M | $4.9M | $5.0M | $2.3M | $2.3M | $2.5M | $5.1M | $5.1M | $1.9M | $1.9M | $4.9M | $2.5M |
| Sales, general & admin | $3.5M | $2.0M | $2.3M | $1.74B | $1.7M | $2.8M | $3.5M | $3.5M | $3.4M | $3.4M | $4.8M | $2.7M |
| Total operating expenses | $3.2M | $6.9M | $7.4M | $4.1M | $4.0M | $5.3M | $8.6M | $8.6M | $5.3M | $5.3M | $9.7M | $5.1M |
| Operating income | −$3.2M | −$6.9M | −$7.4M | −$4.1M | −$1.2M | −$5.2M | −$8.5M | −$8.5M | −$5.2M | −$5.2M | −$9.6M | −$5.1M |
| Income before taxes | −$3.1M | −$7.1M | −$7.4M | −$4.0M | −$915,000 | $21.5M | −$8.5M | −$8.5M | −$5.0M | −$5.0M | −$8.9M | −$4.7M |
| Income taxes | — | — | — | — | — | — | — | — | — | −$39,276 | −$39,812 | $44,586 |
| Net income | −$3.1M | −$3.1M | −$7.4M | −$3.0M | −$915,000 | $15.1M | −$8.5M | −$8.5M | −$5.0M | −$5.0M | −$8.9M | −$4.7M |
| EBITDA | −$3.1M | −$6.9M | −$7.3M | −$4.0M | −$1.2M | $21.5M | −$8.5M | −$8.5M | −$5.2M | −$5.2M | −$9.3M | −$5.1M |
| EPS (diluted) | −$0.16 | −$0.52 | −$0.55 | −$0.34 | −$0.16 | $2.09 | $26.60 | −$8.81 | −$121.75 | −$5.00 | −$0.19 | −$5.75 |
| Gross margin | — | 100.0% | — | — | 100.0% | 98.2% | 96.5% | 96.5% | 100.0% | 100.0% | 96.5% | 100.0% |
| Operating margin | — | −12,186.0% | — | — | −45.7% | −9,128.1% | −14,975.4% | −14,975.4% | −9,307.1% | −9,307.1% | −8,452.2% | −8,928.1% |
| Net margin | — | −5,357.9% | — | — | −33.5% | 26,461.4% | −14,868.4% | −14,868.4% | −8,898.2% | −8,898.2% | −7,896.5% | −8,314.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TRAW's financial statements (latest annual report filed April 15, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TRAW financial results
In fiscal year 2025 (ended December 31, 2025), Traws Pharma reported revenue of $2.8 million, up 1,134.5% from the year before. It had net income of $9.2 million, a net profit margin of 328.7%. Diluted earnings per share came to $1.04. Over five years revenue grew at an average rate of 64.6% a year.
See the TRAW stock overview for the latest quote and news, or the TRAW chart for price history and technical indicators.
TRAW income statement FAQ
What is Traws Pharma's annual revenue?
Traws Pharma reported total revenue of $2.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 1,134.5% from $0.2 million the previous year.
Is Traws Pharma profitable?
Yes. Traws Pharma reported net income of $9.2 million in fiscal 2025, a net profit margin of 328.7%; its operating margin was −640.7%.
What is Traws Pharma's gross margin?
Traws Pharma's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Traws Pharma kept $100 after the direct cost of its products and services.
How much does Traws Pharma spend on research and development?
Traws Pharma spent $12.1 million on research and development in fiscal 2025, 435.2% of revenue.
How fast is Traws Pharma growing?
Revenue grew 64.6% a year on average over the last five fiscal years, from $0.2 million to $2.8 million.
What are Traws Pharma's earnings per share?
Traws Pharma earned $1.04 per diluted share in fiscal 2025, compared with $-108.96 a year earlier.
When will Traws Pharma report its next earnings?
Traws Pharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Traws Pharma's fiscal year end?
Traws Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 15, 2026.